RESEARCH GOVERNANCE/RESEARCH & DEVELOPMENT SUB-COMMITTEE TERMS OF REFERENCE

Transcription

1 HYWEL DDA UNIVERSITY HEALTH BOARD AUDIT & RISK BUSINESS PLANNING & PERFORMANCE CHARITABLE FUNDS MENTAL HEALTH LEGISLATION PRIMARY CARE APPLICATIONS QUALITY, SAFETY & EXPERIENCE REMUNERATION & TERMS OF SERVICE UNIVERSITY PARTNERSHIP BOARD Research Governance/ Research & Development Sub-Committee RESEARCH GOVERNANCE/RESEARCH & DEVELOPMENT SUB- TERMS OF REFERENCE Version Issued to: Date Comments V0.2 Research & Development Committee V0.3 Research & Development Committee V0.4 University Partnership Board

2 RESEARCH GOVERNANCE/RESEARCH & DEVELOPMENT SUB- 1. Constitution 1.1 The Research Governance/Research & Development Sub-Committee has been established as a Sub-Committee of the University Partnership Board and constituted from 1 st June Membership 2.1 The membership of the Sub-Committee shall comprise: Title R&D Director (Chair) Deputy R&D Director (Vice Chair) Independent Member Quality Assurance Officer R&D Manager/s Portfolio Research Coordinator Head of Consent & Mental Capacity Assistant Director of Nursing (with a responsibility for research) Assistant Director of Therapies and Health Science (with a responsibility for research) Lay representative Medical representatives Associate Medical Director (with responsibility for R&D) Representatives from Service Support areas Representatives from all local Universities Finance Manager Clinical Trials Nurse Head of Medical Education and Knowledge Representatives from the Division for Social Care and Health Research (DSCHR) Welsh Government - Health and Care Research Wales Workforce 2.2 Membership of the Sub-Committee will be reviewed on an annual basis. 3. Quorum and Attendance 3.1 A quorum shall consist of no less than half of the membership, and must include as a minimum the Chair or Vice-Chair of the Sub-Committee. 3.2 An Independent Member shall attend the meeting in a scrutiny capacity. 3.3 Any senior officer of the UHB or partner organisation may, where appropriate, be invited to attend, for either all or part of a meeting, to assist with discussions on a particular matter. 3.4 The Sub-Committee may also co-opt additional independent external experts from outside the organisation to provide specialist skills.

3 3.5 Should any officer member be unavailable to attend, they may nominate a deputy with full voting rights to attend in their place, subject to the agreement of the Chair. 3.6 The Chair of the Research Governance/Research & Development Sub-Committee shall have reasonable access to Executive Directors and other relevant senior staff. 3.7 The Sub-Committee may ask any or all of those who normally attend but who are not members to withdraw to facilitate open and frank discussion of particular matters. 4. Purpose 4.1 The purpose of the Research Governance/Research & Development Sub-Committee will be to assure the Board, via the University Partnership Board, that it is discharging its functions and meeting its responsibilities with regards to the quality and safety of research activity carried out within the organisation. 4.1 The purpose of the R&D Committee is to promote and support involvement in high quality healthcare research, to promote evidence-based healthcare, to build research capacity and to foster a research culture. The R&D Committee aims to promote high quality research and development, and oversee its organisation in the Health Board. 5. Key Responsibilities 5.1 Assure the Board in relation to arrangements for ensuring compliance with all relevant frameworks, UK Clinical Trials and other Regulations (transposed into UK law from European Union Directives) and reporting requirements. 5.2 Consider the implications for the Board of the outcomes arising from relevant review, audit or inspection carried out by external regulatory authorities, review progress with resulting Corrective And Preventative Action plans (CAPAs) and authorising their completion. 5.3 Oversee the development of the Board s Research and Development (R&D)Strategy, R&D Policies, Standard Operating Procedures and other relevant documents in line with local and national priorities and guidance, for sign off by the Board after scrutiny from the University Partnership Board. 5.4 Ensure strong relationships and effective communication with associated Higher Education Institutions and other external organisations. 5.5 Promote the dissemination of research findings in order to contribute to clinical effectiveness and evidence-based healthcare delivery. 5.6 Agree issues to be escalated to the University Partnership Board with recommendations for action. 5.1 The R&D Committee will provide assurance to the Board that the ring fenced R&D Activity Based Funding is being spent according to Welsh Government requirements. 5.2 The principal duties of the Research & Development Committee are to: Ensure R&D is appropriately resourced and that resources are channelled to local and national R&D priorities in the health community.

4 5.2.2 Report to relevant agencies such as the Division for Health and Social Care Research (DSCHR), Welsh Government, through the approval of the R&D Annual Return, Mid Year Return and annual Spending Plan Receive and comment on financial, performance management and data reports submitted to DSCHR or Health and Care Research Wales Discuss and approve a local R&D Strategy, Standard Operating Procedures and other relevant documents in line with local and national priorities and guidance To review new research applications pertaining to a member s specialist field / management responsibilities when requested by the R&D Manager Promote increased staff involvement in research activity, including facilitating access to relevant training to enhance research capacity and capability Encourage multi-disciplinary and multi-agency R&D, including patient/public involvement where appropriate Ensure strong relationships and effective communication with associated Higher Education Institutions and other external organisations Promote the dissemination of research findings in order to contribute to clinical effectiveness and evidence-based healthcare delivery Report on R&D activity to relevant health community committees and Health Board via the R&D Director or their nominated person. 5.3 The Committee will, in respect of its provision of assurance and advice to the University Partnership Board, ensure the implementation and adherence to relevant research legislation and any requests for reports to DSCHR. 6. Agenda and Papers 6.1 The Sub-Committee Secretary is to hold an agenda setting meeting with the Chair and/or the Vice Chair and the R&D Director, at least four weeks before the meeting date. 6.2 The agenda will be based around the Sub-Committee work plan, identified risks, matters arising from previous meetings, issues emerging throughout the year and requests from Sub-Committee members. Following approval, the agenda and timetable for papers will be circulated to all Sub-Committee members. 6.3 All papers must be approved by the relevant R&D Manager. 6.4 The agenda and papers for meetings will be distributed seven days in advance of the meeting. 6.5 The minutes and action log will be circulated to members within ten days to check the accuracy. 6.6 Members must forward amendments to the Sub-Committee Secretary within the next seven days. The Sub-Committee Secretary will then forward the final version to the Sub- Committee Chair for approval.

5 7. Frequency of Meetings 7.1 The Sub-Committee will meet four times a year and shall agree an annual schedule of meetings. Any additional meetings will be arranged as determined by the Chair of the Sub-Committee in discussion with the R&D Director. 7.2 The Chair of the Sub-Committee, in discussion with the Sub-Committee Secretary, shall determine the time and the place of meetings of the Sub-Committee and procedures of such meetings. 8. Accountability, Responsibility and Authority 8.1 The Sub-Committee will be accountable to the University Partnership Board for its performance in exercising the functions set out in these terms of reference. 8.2 The Sub-Committee shall embed the UHB s vision, corporate standards, priorities and requirements, e.g. equality and human rights, through the conduct of its business. 8.3 The requirements for the conduct of business as set out in the UHB s Standing Orders are equally applicable to the operation of the Sub-Committee. 9. Reporting 9.1 The Sub-Committee, through its Chair and members, shall work closely with the Board s other committees, including joint /sub committees and groups to provide advice and assurance to the Board through the: joint planning and co-ordination of Board and Committee business; sharing of information; 9.2 In doing so, the Sub-Committee shall contribute to the integration of good governance across the organisation, ensuing that all sources of assurance are incorporated into the Board s overall risk and assurance framework. 9.3 The Sub-Committee may establish sub-groups or task and finish groups to carry out on its behalf specific aspects of Sub-Committee business. The Sub-Committee will receive an update following each Group s meetings detailing the business undertaken on its behalf. The following Groups have been established: Sponsor Review Panel Medicines and Healthcare Products Regulatory Agency (MHRA) Task & Finish Group Human Tissue Authority Task & Finish Group 9.4 The Sub-Committee Chair, supported by the Sub-Committee Secretary, shall: Report formally, regularly and on a timely basis to the University Partnership Board on the Sub-Committee s activities. This includes the submission of Sub- Committee update report as well as the presentation of an annual report within 6 weeks of the end of the financial year; Bring to the University Partnership Board s specific attention any significant matters under consideration by the Sub-Committee; Ensure appropriate escalation arrangements are in place to alert the UHB Chair, Chief Executive, or Chair of other relevant Committees, of any urgent/critical

6 matters that may compromise patient care and affect the operation and/or reputation of the UHB. 10. Secretarial Support 10.1 The Sub-Committee Secretary shall be determined by the R&D Director. 11. Review Date 11.1 These terms of reference and operating arrangements shall be reviewed on at least an annual basis by the Sub-Committee for approval by the University Partnership Board.